Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age

Human Vaccines

Volumn 5, Issue 1, 2009, Pages 18-25

  Kilpi, Terhi M ^a   Silfverdal, Sven Arne ^b   Nilsson, Lennart ^c   Syrjänen, Ritva ^a   Belloni, Cesare ^d   Desole, Maria ^e   Triban, Chiara ^f   Storsaeter, Jann ^f   Soila, Maaria ^f   Jacquet, Jeanne Marie ^f,g,h,i   Lahdenkari, Mika ^a   Käyhty, Halena ^a   Ölander, Rose Marie ^a   Uotila, Tapio ^a   Strömberg, Nina ^a   Sivonen, Liisa ^a   Lipponen, Seija ^a   Holm, Anne ^a   Grönholm, Sinikka ^a   Miikkulainen, Maija ^a   Miinalainen, Aila ^a   Gabuti, Giovanni ^j   Faldella, Giacomo ^j   De Mattia, Domenico ^j   Helander, Christina ^j   Lindell, Lena ^j   Lundell, Catarina ^j   Ekholm, Leif ^j   Fjällryd, Laila ^j   Tinglöf, Göran ^j   more..

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e Public Health Service AUSL 1   (Italy)

^f GSK   (Italy)

^g GLAXOSMITHKLINE   (United Kingdom)

^h GLAXOSMITHKLINE   (Finland)

ⁱ GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^j NONE

more..

Author keywords

Antibodies; Combination vaccines; Immunization schedule; Infant

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA TOXOID; HEPATITIS B SURFACE ANTIGEN; PERTACTIN; PERTUSSIS TOXIN; POLIOMYELITIS VACCINE; TETANUS TOXOID; VIRUS HEMAGGLUTININ; BACTERIUM ANTIBODY; VACCINE; VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; ANOREXIA; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DROWSINESS; DRUG DOSAGE FORM COMPARISON; DRUG FEVER; DRUG FORMULATION; DRUG RESPONSE; FEMALE; FINLAND; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; IRRITABILITY; ITALY; MALE; MULTICENTER STUDY; NORMAL HUMAN; PAIN; PERTUSSIS; POLIOMYELITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN REDNESS; SWEDEN; SWELLING; TETANUS; VACCINATION REACTION; BLOOD; COMPARATIVE STUDY; IMMUNIZATION; IMMUNOLOGY;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; FINLAND; HUMANS; IMMUNIZATION, SECONDARY; INFANT; ITALY; SWEDEN; VACCINES, COMBINED;

EID: 63349092540     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.1.6369     Document Type: Article

References (42)

1. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999; 354:2063-8.
2. Granoff DM. Assessing efficacy of Haemophilus influenzae type b combination vaccines. Clin Infect Dis 2001; 33:278-87.
3. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355:561-5.
4. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children and adolescents. MMWR Recomm Rep 2005; 54:1-31.
5. Tichmann I, Preidel H, Grunert D, Habash S, Schult R, Maier R, Gildberg PK, Sengespeik HC, Meurice F, Sanger R. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 2005; 23:3272-9.
6. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000; 19:877-85.
7. Duval B, Gilca V, Boulianne N, De Wals P, Masse R, Trudeau G, De Serres G. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J 2005; 24:213-8.
8. van der Sande MA, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, Doherty C, McConkey SJ, Jeffries D, Hall AJ, Whittle HC. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 2006; 193:1528-35.
9. European Medicines Agency recommends suspension of Hexavac. European Medicines Agency 2005.
10. Carlsson RM, Claesson BA, Selstam U, Fagerlund E, Granstrom M, Blondeau C, Hoffenbach A. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998; 17:1026-33.
11. Carlsson RM, Claesson BA, Kayhty H, Selstam U, Iwarson S. Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine. Vaccine 1999; 18:468-78.
12. Knutsson N, Trollfors B, Taranger J, Bergfors E, Sundh V, Lagergard T, Ostergaard E, Cicirello H, Kayhty H. Immunogenicity and reactogenicity of diphtheria, tetanus and pertussis toxoids combined with inactivated polio vaccine, when administered concomitantly with or as a diluent for a Hib conjugate vaccine. Vaccine 2001; 19:4396-403.
13. Kayhty H, Ahman H, Eriksson K, Sorberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 2005; 24:108-14.
14. Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 2006; 24:4727-36.
15. Goldblatt D, Miller E, McCloskey N, Cartwright K. Immunological response to conjugate vaccines in infants: follow up study. BMJ 1998; 316:1570-1.
16. Tichmann-Schumann I, Soemantri P, Behre U, Disselhoff J, Mahler H, Maechler G, Sanger R, Jacquet JM, Schuerman L. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine. Pediatr Infect Dis J 2005; 24:70-7.
17. Tichmann I, Grunert D, Habash S, Preidel H, Schult R, Pfletschinger U, Gildberg PK, Meurice F, Sanger R. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination. Human vaccines 2006; 2:249-54.
18. Omenaca F, Garcia-Sicilia J, Garcia-Corbeira P, Boceta R, Torres V. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine. Pediatrics 2007; 119:179-85.
19. Chief Medical Officer, Chief Nursing Officer, Chief Pharmaceutical Officer. Planned changes to the routine Childhood Immunisation Programme 2006.
20. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188:481-5.
21. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361:1521-3.
22. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113:163-74.
23. Chief Medical Officer, Chief Nursing Officer, Chief Pharmaceutical Officer. Important changes to the Childhood Immunisation Programme 2006.
24. Garpenholt O, Hugosson S, Fredlund H, Giesecke J, Olcen P. Invasive disease due to Haemophilus influenzae type b during the first six years of general vaccination of Swedish children. Acta Paediatr 2000; 89:471-4.
25. Farhoudi D, Lofdahl M, Giesecke J. Invasive Haemophilus influenzae type b disease in Sweden 1997-2003: epidemiological trends and patterns in the post-vaccine era. Scand J Infect Dis 2005; 37:717-22.
26. Vidor E, Hoffenbach A, Fletcher MA. Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary series immunisation schedule, may modify the serum anti-PRP antibody responses. Curr Med Res Opin 2001; 17:197-209.
27. Lee YC, Kelly DF, Yu LM, Slack MP, Booy R, Heath PT, Siegrist CA, Moxon RE, Pollard AJ. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis 2008; 46:186-92.
28. Siegrist CA. The challenges of vaccine responses in early life: selected examples. J Comp Pathol 2007; 137:4-9.
29. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16:1901-6.
30. Storsaeter J, Hallander HO, Gustafson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16:1907-16.
31. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003; 21:2003-14.
32. Desauziers E, Hessel L, Decker MD, Caro JJ, Liese JG. Systematic review of the effects of pertussis vaccines in children. Vaccine 2004; 22:2681-4.
33. Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glode MP, Ehresmann KR. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics 2005; 116:285-94.
34. Taranger J, Trollfors B, Bergfors E, Knutsson N, Sundh V, Lagergard T, Lind-Brandberg L, Zackrisson G, White J, Cicirello H, Fusco J, Robbins JB. Mass vaccination of children with pertussis toxoid - decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 2001; 33:1004-10.
35. Hovi T. Inactivated poliovirus vaccine and the final stages of poliovirus eradication. Vaccine 2001; 19:2268-72.
36. Sormunen H, Stenvik M, Eskola J, Hovi T. Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. J Med Virol 2001; 63:305-10.
37. Lankinen KS. Scientific and technical evaluation of vaccinations programmes in the European Union. EUVAX Project Report. Helsinki: PSR Consulting Ltd 2001.
38. Mele A, Jefferson T, Franco E, Salmaso S. Change from oral poliovirus vaccine to inactivated poliovirus vaccine. Lancet 2002; 360:1178.
39. McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988; 128:615-28.
40. Moriniere BJ, van Loon FP, Rhodes PH, Klein-Zabban ML, Frank-Senat B, Herrington JE, Pallansch MA, Patriarca PA. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 1993; 341:1545-50.
41. Lackmann GM. Comparative investigation of the safety of hexavalent vaccines for primary scheduled infant immunizations in Germany over a time period of 2 years. Med Sci Monit 2004; 10:96-8.
42. Altman DG, Bland JM. Treatment allocation by minimisation. BMJ 2005; 330:843.